Payment overview · 2025
General Payments
$357.40
13 reported records · 11 companies
Healthcare provider profile · identity verified
Simona Daniela Alb, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHULA VISTA, CA · NPI 1578641874
Verified facts
What the public records show
CMS Open Payments records show Simona Daniela Alb, MD received $357.40 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $125.00 | 35.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $37.50 | 10.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.76 | 8.3% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $26.39 | 7.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.03 | 7.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $25.02 | 7.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.20 | 5.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.36 | 5.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.46 | 4.9% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $16.07 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.61 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.40 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.76 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $26.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
53 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 97 |
| Losartan Potassium | Losartan Potassium | 317 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 82 |
| Metformin Hcl | Metformin Hcl | 240 | 84 |
| Lisinopril | Lisinopril | 149 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 44 |
| Alendronate Sodium | Alendronate Sodium | 128 | 45 |
| Omeprazole | Omeprazole | 128 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 42 |
| Simvastatin | Simvastatin | 102 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 26 |
| Trazodone Hcl | Trazodone Hcl | 93 | 29 |
| Gabapentin | Gabapentin | 90 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 28 |
| Ibuprofen | Ibuprofen | 71 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 21 |
| Chlorthalidone | Chlorthalidone | 60 | 20 |
| Jardiance | Empagliflozin | 54 | 16 |
| Lorazepam | Lorazepam | 54 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 23 |
| Telmisartan | Telmisartan | 51 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Furosemide | Furosemide | 48 | 18 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 15 |
| Famotidine | Famotidine | 43 | 16 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 42 | 41 |
| Atenolol | Atenolol | 42 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | 14 |
| Eliquis | Apixaban | 41 | 15 |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Carvedilol | Carvedilol | 25 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Potassium Chloride | Potassium Chloride | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Valsartan | Valsartan | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.40 · 13 records | Abbott Laboratories | AIRSUPRA, APTIMA, AREXVY, AVEIR, Hillrom - Cardiac Ambulatory Monitor, QULIPTA, REXULTI, SHINGRIX, TZIELD, UBRELVY, Veozah, bio-ConneKt | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error